Century Therapeutics, Inc. (IPSC)
1.45
+0.03
(+2.11%)
USD |
NASDAQ |
Oct 27, 16:00
1.445
0.00 (0.00%)
After-Hours: 20:00
Century Therapeutics Enterprise Value : 180.75M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 180.75M |
| October 26, 2026 | 175.33M |
| October 23, 2026 | 182.55M |
| October 22, 2026 | 204.22M |
| October 21, 2026 | 209.64M |
| October 20, 2026 | 215.05M |
| October 19, 2026 | 184.36M |
| October 16, 2026 | 166.30M |
| October 15, 2026 | 189.78M |
| October 14, 2026 | 168.11M |
| October 13, 2026 | 168.11M |
| October 12, 2026 | 178.94M |
| October 09, 2026 | 184.36M |
| October 08, 2026 | 182.55M |
| October 07, 2026 | 150.05M |
| October 06, 2026 | 157.28M |
| October 05, 2026 | 186.16M |
| October 02, 2026 | 195.19M |
| October 01, 2026 | 209.64M |
| September 30, 2026 | 227.69M |
| September 29, 2026 | 216.86M |
| September 28, 2026 | 220.47M |
| September 25, 2026 | 220.47M |
| September 24, 2026 | 224.08M |
| September 23, 2026 | 236.72M |
| Date | Value |
|---|---|
| September 22, 2026 | 260.19M |
| September 21, 2026 | 252.97M |
| September 18, 2026 | 254.77M |
| September 17, 2026 | 258.38M |
| September 16, 2026 | 254.77M |
| September 15, 2026 | 276.44M |
| September 14, 2026 | 280.05M |
| September 11, 2026 | 269.22M |
| September 10, 2026 | 269.22M |
| September 09, 2026 | 285.47M |
| September 08, 2026 | 292.69M |
| September 04, 2026 | 299.91M |
| September 03, 2026 | 296.30M |
| September 02, 2026 | 299.91M |
| September 01, 2026 | 285.47M |
| August 31, 2026 | 289.08M |
| August 28, 2026 | 284.56M |
| August 27, 2026 | 321.57M |
| August 26, 2026 | 305.33M |
| August 25, 2026 | 310.74M |
| August 24, 2026 | 301.71M |
| August 21, 2026 | 292.69M |
| August 20, 2026 | 283.66M |
| August 19, 2026 | 299.91M |
| August 18, 2026 | 272.83M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -63.02M |
| Exicure, Inc. | 5.103M |
| Absci Corp. | 1.616B |
| Celularity, Inc. | 92.39M |
| Cardio Diagnostics Holdings, Inc. | -0.1859M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.55M |
| Total Expenses (Quarterly) | 34.55M |
| EPS Diluted (Quarterly) | -0.1679 |
| Earnings Yield | -61.86% |
| Normalized Earnings Yield | -58.95 |